Arix Bioscience PLC has released its unaudited estimated Net Asset Value (NAV) for September 2023. The NAV breakdown for the company as of September 30, 2023, is as follows: Total NAV of £55.9 million, with a NAV per share of £1.80. The listed portfolio is valued at £67.6 million, the unlisted portfolio at £106.0 million, and the cash position at £2.9 million. Other interests are valued at £232.4 million. Arix Bioscience is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies. They collaborate with entrepreneurs and provide capital, expertise, and global networks to accelerate the development of new treatments for patients. Arix Bioscience is listed on the London Stock Exchange.